Partial-Thickness Burn, Thermal BurnNCT07367087
Silver Sulfadiazine With Hyaluronic Acid Versus Silver Sulfadiazine Alone in Partial-Thickness Burns
A study testing Silver Sulfadiazine With Hyaluronic Acid and Silver Sulfadiazine in people with Partial-Thickness Burn, Thermal Burn, run by Dr Muhammad Naveed Shahzad at 1 site in Pakistan.
Trial summary
Partial-thickness burns are commonly treated with topical silver sulfadiazine; however, its use may delay epithelialization due to cytotoxic effects on regenerating cells. Hyaluronic acid has biological properties that may enhance wound healing when combined with silver sulfadiazine. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Partial-Thickness Burn, Thermal Burn
- What is being tested?
- Silver Sulfadiazine With Hyaluronic Acid and Silver Sulfadiazine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 sitePakistan
- Study dates
- Feb 2026to Oct 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patients with acute bilateral partial-thickness (second-degree) thermal burns where both sides/areas are comparable and suitable for intra-patient treatment (one area treated with SSD+HA and the contralateral area with SSD alone)
- Presentation within 72 hours of burn injury
- Small to moderate total burn surface area suitable for conservative topical management
- Burn wounds not requiring immediate excision or grafting at baseline
- Ability to comply with daily dressing application and follow-up until complete re-epithelialization
- Written informed consent from patient; for minors, parent/guardian consent and assent where applicable
Who cannot join
- Full-thickness (third-degree) burns or mixed-depth burns in the study areas
- Chemical, electrical, radiation, or inhalational burns requiring ICU or ventilatory support
- Infected burn wounds at baseline requiring systemic antibiotics
- Major comorbidities likely to impair wound healing (e.g., uncontrolled diabetes, severe peripheral vascular disease, immunosuppression, severe malnutrition)
- Known hypersensitivity to silver sulfadiazine, sulfonamides, hyaluronic acid, or formulation components
- Pregnancy or lactation (as per institutional policy)
- Non-comparable bilateral burn wounds
- Concurrent participation in another interventional wound or burn study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Pakistan1 site
Nishtar Medical University & Hospital, Multan
Multan, Punjab Province, 60000
Muhammad N Shahzad, MBBS,MCPS,FCPS,FCPS, +92-331-7020877, drnaveedkhanlodhi@gmail.com
About this study
Official title: A Prospective Intra-Patient Randomized Controlled Trial Comparing Silver Sulfadiazine Combined With Hyaluronic Acid Versus Silver Sulfadiazine Alone in Bilateral Partial-Thickness Burns
Partial-thickness burns are commonly treated with topical silver sulfadiazine; however, its use may delay epithelialization due to cytotoxic effects on regenerating cells. Hyaluronic acid has biological properties that may enhance wound healing when combined with silver sulfadiazine. This study aims to compare the time to re-epithelialization between silver sulfadiazine combined with hyaluronic acid and silver sulfadiazine alone in patients with bilateral partial-thickness burns using an intra-patient randomized controlled design.
Read the detailed description
This is a prospective, intra-patient randomized controlled clinical trial conducted at a tertiary care burn center. Patients of all ages presenting with bilateral, symmetrical partial-thickness thermal burns will be enrolled, provided the burn areas are clinically comparable and suitable for intra-patient randomized treatment.
In each patient, one burn area will be randomly assigned to receive topical silver sulfadiazine combined with hyaluronic acid, while the contralateral burn area will receive silver sulfadiazine alone.
Randomization will be performed at the wound level so that each participant serves as their own control, minimizing inter-individual variability. Both interventions will be applied using identical dressing techniques and schedules. The primary outcome measure is time to re-epithelialization, defined as the number of days from initiation of treatment to achievement of complete epithelial coverage of the wound surface.
Participants will be monitored daily until epithelialization is complete. This study is designed to evaluate whether the addition of hyaluronic acid to standard silver sulfadiazine therapy accelerates wound healing in partial-thickness burns under routine clinical conditions.
- Conditions
- Partial-Thickness Burn, Thermal Burn
- Being tested
- Silver Sulfadiazine With Hyaluronic Acid, Silver Sulfadiazine
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Silver Sulfadiazine With Hyaluronic AcidDrug
Topical application of silver sulfadiazine combined with hyaluronic acid applied once daily until complete re-epithelialization.
Silver SulfadiazineDrug
Topical application of silver sulfadiazine applied once daily until complete re-epithelialization.
| Study group | Role | What they receive |
|---|---|---|
| Silver Sulfadiazine Plus Hyaluronic Acid | Experimental | Intra-patient burn areas treated with topical silver sulfadiazine combined with hyaluronic acid. Receives: Drug: Silver Sulfadiazine With Hyaluronic Acid |
| Silver Sulfadiazine Alone | Active comparator | Intra-patient burn areas treated with topical silver sulfadiazine alone. Receives: Drug: Silver Sulfadiazine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to Complete Re-epithelialization
Time (in days) from initiation of topical treatment to complete re-epithelialization of the partial-thickness burn wound, defined as full epithelial cover without exudate.
Measured: Up to 21 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jan 2026
- Study startFeb 2026 (estimated)
- Primary completionAug 2026 (estimated)
- Study completionOct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Partial-Thickness Burn, Thermal BurnStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Intra-patient randomized controlled design in which each participant receives both interventions applied to bilateral burn wounds.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Dr Muhammad Naveed Shahzad
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Dr Muhammad Naveed Shahzad, Nishtar Medical University
- Investigators
- Muhammad N Shahzad, MBBS, MCPS,FCPS,FCPS, Principal investigator, Department of Plastic Surgery, Nishtar Medical University / Nishtar Hospital Multan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07367087
- Sponsor's protocol ID
- SSDHA-PTB-2026
- Status last verified
- Jan 2026
- First submitted
- 16 Jan 2026
- Last updated
- 26 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Intra-Patient Randomized Controlled Trial Comparing Silver Sulfadiazine Combined With Hyaluronic Acid Versus Silver Sulfadiazine Alone in Bilateral Partial-Thickness Burns
- ClinicalTrials.gov ID
- NCT07367087
- Acronym / sponsor ID
- SSDHA-PTB-2026
- Conditions
- Partial-Thickness Burn, Thermal Burn
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Dr Muhammad Naveed ShahzadUniversity, hospital or other
- Study start
- Feb 2026 (estimated)
- Primary completion
- Aug 2026 (estimated)
- Study completion
- Oct 2026 (estimated)
- First posted
- 26 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Partial-thickness burns are commonly treated with topical silver sulfadiazine; however, its use may delay epithelialization due to cytotoxic effects on regenerating cells. Hyaluronic acid has biological properties that may enhance wound healing when combined with silver sulfadiazine. This study aims to compare the time to re-epithelialization between silver sulfadiazine combined with hyaluronic acid and silver sulfadiazine alone in patients with bilateral partial-thickness burns using an intra-patient randomized controlled design.
Detailed description
This is a prospective, intra-patient randomized controlled clinical trial conducted at a tertiary care burn center. Patients of all ages presenting with bilateral, symmetrical partial-thickness thermal burns will be enrolled, provided the burn areas are clinically comparable and suitable for intra-patient randomized treatment.
In each patient, one burn area will be randomly assigned to receive topical silver sulfadiazine combined with hyaluronic acid, while the contralateral burn area will receive silver sulfadiazine alone.
Randomization will be performed at the wound level so that each participant serves as their own control, minimizing inter-individual variability. Both interventions will be applied using identical dressing techniques and schedules. The primary outcome measure is time to re-epithelialization, defined as the number of days from initiation of treatment to achievement of complete epithelial coverage of the wound surface.
Participants will be monitored daily until epithelialization is complete. This study is designed to evaluate whether the addition of hyaluronic acid to standard silver sulfadiazine therapy accelerates wound healing in partial-thickness burns under routine clinical conditions.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Intra-patient randomized controlled design in which each participant receives both interventions applied to bilateral burn wounds.
| Arm | Type | Receives |
|---|---|---|
| Silver Sulfadiazine Plus Hyaluronic Acid | Experimental | Drug: Silver Sulfadiazine With Hyaluronic AcidIntra-patient burn areas treated with topical silver sulfadiazine combined with hyaluronic acid. |
| Silver Sulfadiazine Alone | Active comparator | Drug: Silver SulfadiazineIntra-patient burn areas treated with topical silver sulfadiazine alone. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (6 listed)
- Patients with acute bilateral partial-thickness (second-degree) thermal burns where both sides/areas are comparable and suitable for intra-patient treatment (one area treated with SSD+HA and the contralateral area with SSD alone)
- Presentation within 72 hours of burn injury
- Small to moderate total burn surface area suitable for conservative topical management
- Burn wounds not requiring immediate excision or grafting at baseline
- Ability to comply with daily dressing application and follow-up until complete re-epithelialization
Key exclusion criteria (8 listed)
- Full-thickness (third-degree) burns or mixed-depth burns in the study areas
- Chemical, electrical, radiation, or inhalational burns requiring ICU or ventilatory support
- Infected burn wounds at baseline requiring systemic antibiotics
- Major comorbidities likely to impair wound healing (e.g., uncontrolled diabetes, severe peripheral vascular disease, immunosuppression, severe malnutrition)
- Known hypersensitivity to silver sulfadiazine, sulfonamides, hyaluronic acid, or formulation components
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Silver Sulfadiazine With Hyaluronic AcidTopical application of silver sulfadiazine combined with hyaluronic acid applied once daily until complete re-epithelialization. | Drug | Silver Sulfadiazine Plus Hyaluronic Acid |
| Silver SulfadiazineTopical application of silver sulfadiazine applied once daily until complete re-epithelialization. | Drug | Silver Sulfadiazine Alone |
Primary outcome
Time to Complete Re-epithelialization
Time frame: Up to 21 days
Time (in days) from initiation of topical treatment to complete re-epithelialization of the partial-thickness burn wound, defined as full epithelial cover without exudate.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Partial-Thickness Burn, Thermal Burn
RecruitingPhase 3
Phase III Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents
Burns
Active, not recruitingPhase 2
Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Children
Burns
RecruitingPhase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
Burns
RecruitingPhase 3
Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Burn Wounds as an Alternative to Autografting
Burns Degree Third, Burn (Disorder)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Muhammad N Shahzad, MBBS, MCPS,FCPS,FCPS principal investigator
Department of Plastic Surgery, Nishtar Medical University / Nishtar Hospital Multan
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Silver Sulfadiazine With Hyaluronic Acid and Silver Sulfadiazine in people with Partial-Thickness Burn, Thermal Burn, run by Dr Muhammad Naveed Shahzad at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 26 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Muhammad N Shahzad, MBBS, MCPS,FCPS,FCPS (+92-331-7020877, drnaveedkhanlodhi@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to Complete Re-epithelialization (time frame: Up to 21 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2026.